|
3 Resverlogix trials recently updated on ClinicalTrials.gov
|
7
|
Resverlogix Corp.
|
Jan 24, 2019 12:07PM
|
|
30th EORTC-NCI-AACR SYMPOSIUM
|
4
|
Zenith Epigenetics
|
Jun 07, 2018 02:45PM
|
|
3600 patient years
|
8
|
Resverlogix Corp.
|
Feb 16, 2018 03:27PM
|
|
4 Events in the Next 4 to 6 Weeks
|
2
|
Resverlogix Corp.
|
Feb 16, 2019 11:54AM
|
|
5 of 8 Sites Now Recruiting for ZEN-3694/Enzalutamid... Trial
|
3
|
Zenith Epigenetics
|
Feb 23, 2017 03:18PM
|
|
5 year anniversary, ESC 2018 update and Amarin/REDUCE-IT
|
4
|
Resverlogix Corp.
|
Jun 28, 2018 03:22PM
|
|
5-point vs. 3-point MACE
|
7
|
Resverlogix Corp.
|
Oct 19, 2015 10:59AM
|
|
8 Minutes at AHA
|
10
|
Resverlogix Corp.
|
Oct 24, 2019 06:57PM
|
|
8 weeks into ZEN-3694 trial today
|
4
|
Zenith Epigenetics
|
Aug 10, 2016 05:13PM
|
|
96 hours
|
2
|
Resverlogix Corp.
|
Aug 22, 2017 11:02AM
|
|
A birthday present for DM?
|
8
|
Resverlogix Corp.
|
Aug 20, 2019 03:46PM
|
|
A busy four days coming up
|
3
|
Resverlogix Corp.
|
Mar 15, 2019 01:59PM
|
|
A clinical future for RVX-2135 or just a pre-clinical tool
|
6
|
Zenith Epigenetics
|
Aug 11, 2017 01:42PM
|
|
A couple of recent RVX-208 articles related to selective bromodomain inhibition
|
7
|
Resverlogix Corp.
|
Sep 13, 2017 02:00PM
|
|
A couple Q2 events for Zenith
|
1
|
Zenith Epigenetics
|
May 09, 2017 08:11PM
|
|
A couple recent epigenetic/bromodoma... reviews from 2018
|
3
|
Resverlogix Corp.
|
Apr 16, 2019 11:00AM
|
|
A fair and optimistic write up on BETonMACE
|
8
|
Resverlogix Corp.
|
Nov 22, 2019 06:58AM
|
|
A few clarifications from IR
|
6
|
Resverlogix Corp.
|
Mar 01, 2019 05:12PM
|
|
A few musings
|
5
|
Resverlogix Corp.
|
May 02, 2017 02:58PM
|
|
A few thoughts on Soliris(Eculizumab) vs. RVX-208 for Compliment-related disease
|
11
|
Resverlogix Corp.
|
Sep 24, 2015 11:07PM
|
